Bayer, Epitomics enter service agreement for antibody technology

Download PDF Copy

May 27 2011

Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare's drug target identification and validation.

"Epitomics has had a long-standing experience with Bayer HealthCare. This new agreement is a major expansion of our collaboration and confirms the success of our premium technology platform," said Guo-Liang Yu, PhD, CEO of Epitomics, Inc.

"Our recent experience with the Epitomics rabbit antibody technology has been impressive and we are very pleased to be expanding our collaboration with Epitomics," said Clive R. Wood, Ph.D., Senior VP and Head of Global Biologics, Bayer HealthCare.

SOURCE Epitomics, Inc.

Posted in: Device / Technology News | Medical Science News

Tags: Antibodies, Antibody, Biotechnology, Healthcare, Monoclonal Antibody, Technology

Comments (0)

Download PDF Copy

Suggested Reading

Next-generation cell-penetrating antibodies could transform cancer treatment

Next-generation cell-penetrating antibodies could transform cancer treatment

New molecule shows promise in protecting mice from influenza

New molecule shows promise in protecting mice from influenza

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Nogo-A inhibition demonstrates potential for spinal cord injury recovery

Nogo-A inhibition demonstrates potential for spinal cord injury recovery

Kyushu University team develops antibody to fight age-related muscle atrophy

Kyushu University team develops antibody to fight age-related muscle atrophy

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

A new era of targeted therapy with antibody–drug conjugates

A new era of targeted therapy with antibody–drug conjugates

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Precision in every drop: Inside Hamilton’s syringe technology